| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
iECURE, Inc., a genome editing company focused on the development of variant-agnostic in vivo targeted gene insertion therapies for the treatment of liver disorders with significant unmet need, today announced that additional data from the ongoingOTC-HOPE clinical trial evaluating its candidate ECUR-506 in neonatal onset ornithine transcarbamylase (OTC) deficiency will be presented at the 6th International Symposium on Urea Cycle Disorders (UCDs), taking place September 1-2, 2025 in Kyoto, Japan, and the 15th International Congress of Inborn Errors of Metabolism (ICIEM), taking place September 3-6, 2025 in Kyoto, Japan.
The poster presentations will build upon data the company originally reported in January 2025 showing that the first infant dosed in the ongoing OTC-HOPE study experienced a complete clinical response as per study protocol.
Posted In: DTIL
